Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors

Overview

Journal J Crohns Colitis

Publisher Oxford University Press

Date 2020 Feb 22

PMID 32083640

Citations 19

Authors

Alba Garrido-Trigo

Azucena Salas

Affiliations

Soon will be listed here.

Abstract

Cytokines can trigger multiple signalling pathways, including Janus tyrosine kinases [JAK] and signal transducers and activators of transcription [STATS] pathways. JAKs are cytoplasmic proteins that, following the binding of cytokines to their receptors, transduce the signal by phosphorylating STAT proteins which enter the nuclei and rapidly target gene promoters to regulate gene transcription. Due to the critical involvement of JAK proteins in mediating innate and adaptive immune responses, these family of kinases have become desirable pharmacological targets in inflammatory diseases, including ulcerative colitis and Crohn's disease. In this review we provide an overview of the main cytokines that signal through the JAK/STAT pathway and the available in vivo evidence on mutant or deleted JAK proteins, and discuss the implications of pharmacologically targeting this kinase family in the context of inflammatory diseases.

Citing Articles

Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium.

Zavoriti A, Miossec P ACR Open Rheumatol. 2025; 7(1):e11790.

PMID: 39800890 PMC: 11725533. DOI: 10.1002/acr2.11790.

Targeting STAT3 signaling pathway by curcumin and its analogues for breast cancer: A narrative review.

Golmohammadi M, Zamanian M, Al-Ani A, Jabbar T, Kareem A, Aghaei Z Animal Model Exp Med. 2024; 7(6):853-867.

PMID: 39219410 PMC: 11680487. DOI: 10.1002/ame2.12491.

JAK inhibitors for inflammatory bowel disease: recent advances.

Honap S, Agorogianni A, Colwill M, Kalyanji Mehta S, Donovan F, Pollok R Frontline Gastroenterol. 2024; 15(1):59-69.

PMID: 38487554 PMC: 10935522. DOI: 10.1136/flgastro-2023-102400.

Are All Janus Kinase Inhibitors for Inflammatory Bowel Disease the Same?.

Honap S, Danese S, Peyrin-Biroulet L Gastroenterol Hepatol (N Y). 2024; 19(12):727-738.

PMID: 38404416 PMC: 10885424.

The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.

Zhao R, Hu Z, Zhang X, Huang S, Yu G, Wu Z Cell Commun Signal. 2024; 22(1):68.

PMID: 38273295 PMC: 10809652. DOI: 10.1186/s12964-023-01421-9.

References

Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Gascan H . Signaling of type II oncostatin M receptor. J Biol Chem. 1997; 272(25):15760-4. DOI: 10.1074/jbc.272.25.15760. View

Darnell Jr J, Kerr I, Stark G . Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994; 264(5164):1415-21. DOI: 10.1126/science.8197455. View

Kusugami K, Matsuura T, West G, Youngman K, Rachmilewitz D, Fiocchi C . Loss of interleukin-2-producing intestinal CD4+ T cells in inflammatory bowel disease. Gastroenterology. 1991; 101(6):1594-605. DOI: 10.1016/0016-5085(91)90397-4. View

Yu H, Jove R . The STATs of cancer--new molecular targets come of age. Nat Rev Cancer. 2004; 4(2):97-105. DOI: 10.1038/nrc1275. View

OShea J, Gadina M, Schreiber R . Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109 Suppl:S121-31. DOI: 10.1016/s0092-8674(02)00701-8. View

Wolanskyj A, Lasho T, Schwager S, McClure R, Wadleigh M, Lee S . JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005; 131(2):208-13. DOI: 10.1111/j.1365-2141.2005.05764.x. View

Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G . Fate of lymphocytes after withdrawal of tofacitinib treatment. PLoS One. 2014; 9(1):e85463. PMC: 3887061. DOI: 10.1371/journal.pone.0085463. View

Sohn S, Barrett K, Van Abbema A, Chang C, Kohli P, Kanda H . A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013; 191(5):2205-16. PMC: 3748334. DOI: 10.4049/jimmunol.1202859. View

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

10.

Notarangelo L, Giliani S, Mazza C, Mella P, Savoldi G, Rodriguez-Perez C . Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev. 2001; 178:39-48. DOI: 10.1034/j.1600-065x.2000.17812.x. View

11.

Haan S, Margue C, Engrand A, Rolvering C, Schmitz-Van de Leur H, Heinrich P . Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol. 2008; 180(2):998-1007. DOI: 10.4049/jimmunol.180.2.998. View

12.

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

13.

Jostins L, Ripke S, Weersma R, Duerr R, McGovern D, Hui K . Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012; 491(7422):119-24. PMC: 3491803. DOI: 10.1038/nature11582. View

14.

DiSanto J, Muller W, Fischer A, Rajewsky K . Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1995; 92(2):377-81. PMC: 42743. DOI: 10.1073/pnas.92.2.377. View

15.

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

16.

Byers M, Shows T, Dalla-Favera R, Krolewski J . tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene. 1990; 5(9):1329-36. View

17.

Geyer H, Mesa R . Therapy for myeloproliferative neoplasms: when, which agent, and how?. Blood. 2014; 124(24):3529-37. DOI: 10.1182/blood-2014-05-577635. View

18.

Horuk R . Molecular properties of the chemokine receptor family. Trends Pharmacol Sci. 1994; 15(5):159-65. DOI: 10.1016/0165-6147(94)90077-9. View

19.

Donnelly R, Sheikh F, Kotenko S, Dickensheets H . The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol. 2004; 76(2):314-21. DOI: 10.1189/jlb.0204117. View

20.

Fuss I, Neurath M, Boirivant M, Klein J, de La Motte C, Strong S . Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996; 157(3):1261-70. View